Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE

Objective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. Methods: Systematic literature review (SLR), nom...

ver descrição completa

Detalhes bibliográficos
Autores: Puente, J, Anido, U, Climent, MA, Gonzalez-Billalabeitia, E, Lainez, N, Lambea, J, Maroto, JP, Mendez-Vidal, MJ, Montesa, A, Rodriguez, A, Zambrana, C, Gonzalez-del-Alba, A
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p2022
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2022
https://zaguan.unizar.es/record/89812
Access Level:acceso abierto
Palavra-chave:abiraterone acetate
androgen-deprivation therapy
chemotherapy
enzalutamide
metastatic castration-resistant prostate cancer
radium-223
id ES_7f059ca8eee996fe3f78800e19ccd4f6
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p2022
network_acronym_str ES
network_name_str España
repository_id_str
spelling Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDEPuente, JAnido, UCliment, MAGonzalez-Billalabeitia, ELainez, NLambea, JMaroto, JPMendez-Vidal, MJMontesa, ARodriguez, AZambrana, CGonzalez-del-Alba, Aabiraterone acetateandrogen-deprivation therapychemotherapyenzalutamidemetastatic castration-resistant prostate cancerradium-223Objective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. Methods: Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted > 7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted. Results: The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations. Conclusions: In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms.SAGE PUBLICATIONS LTD2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2022https://zaguan.unizar.es/record/89812Therapeutic Advances in Medical OncologyISSN: 17588340ISSNe: 17588359reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p20222026-06-14T12:41:47Z
dc.title.none.fl_str_mv Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
title Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
spellingShingle Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
Puente, J
abiraterone acetate
androgen-deprivation therapy
chemotherapy
enzalutamide
metastatic castration-resistant prostate cancer
radium-223
title_short Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
title_full Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
title_fullStr Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
title_full_unstemmed Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
title_sort Expert recommendations on the management of patients with metastatic castration-resistant prostate cancer who progress after CHAARTED or LATITUDE
dc.creator.none.fl_str_mv Puente, J
Anido, U
Climent, MA
Gonzalez-Billalabeitia, E
Lainez, N
Lambea, J
Maroto, JP
Mendez-Vidal, MJ
Montesa, A
Rodriguez, A
Zambrana, C
Gonzalez-del-Alba, A
author Puente, J
author_facet Puente, J
Anido, U
Climent, MA
Gonzalez-Billalabeitia, E
Lainez, N
Lambea, J
Maroto, JP
Mendez-Vidal, MJ
Montesa, A
Rodriguez, A
Zambrana, C
Gonzalez-del-Alba, A
author_role author
author2 Anido, U
Climent, MA
Gonzalez-Billalabeitia, E
Lainez, N
Lambea, J
Maroto, JP
Mendez-Vidal, MJ
Montesa, A
Rodriguez, A
Zambrana, C
Gonzalez-del-Alba, A
author2_role author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv abiraterone acetate
androgen-deprivation therapy
chemotherapy
enzalutamide
metastatic castration-resistant prostate cancer
radium-223
topic abiraterone acetate
androgen-deprivation therapy
chemotherapy
enzalutamide
metastatic castration-resistant prostate cancer
radium-223
description Objective: Our aim was to provide practical recommendations on the management of patients with metastatic castration-resistant prostate cancer (mCRPC) who have progressed after docetaxel plus androgen-deprivation therapy (ADT) or abiraterone plus ADT. Methods: Systematic literature review (SLR), nominal group meeting, and Delphi process. A panel of 12 experts was established who defined the scope, users, and sections of the document. We performed an SLR in order to assess the efficacy and safety of available drugs in patients with mCRPC. Abstracts from the American Society of Oncology and European Society for Medical Oncology meetings were also examined. The results were discussed during an expert meeting in which 14 recommendations were generated. The level of agreement with the recommendations was also tested by 13 additional experts following the Delphi process. Recommendations were voted by means of scores ranging from 0 (total disagreement) to 10 (total agreement). We defined agreement when at least 70% of the experts voted > 7. Next, we assigned a level of evidence and grade to the recommendation using the Oxford Centre for Evidence-based Medicine Levels of Evidence, following which the final document was drafted. Results: The literature search did not find any articles meeting the inclusion criteria. Finally, 13 out of 14 recommendations were accepted after two Delphi rounds (two were modified after the first round). They pertain to general and individual case-based treatment recommendations. Conclusions: In mCRPC patients who have progressed after docetaxel or abiraterone plus ADT in the metastatic hormone-sensitive prostate cancer setting, these recommendations may support treatment decision-making, due to the lack of evidence or other globally accepted sequencing algorithms.
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2022
https://zaguan.unizar.es/record/89812
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=2022
https://zaguan.unizar.es/record/89812
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
publisher.none.fl_str_mv SAGE PUBLICATIONS LTD
dc.source.none.fl_str_mv Therapeutic Advances in Medical Oncology
ISSN: 17588340
ISSNe: 17588359
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869411793354358784
score 15.811543

Registos relacionados